17,261 trials
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12) — 100.0; 100.0; 68.8; 71.4 Percentage of Participants
Renal Cell Carcinoma
Primary: Percentage of Participants With Disease Progression Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Via Independent Review Committee (IRC)…
Chronic Lymphocytic Leukemia
Primary: Percentage of Participants With Complete Response (CR), as Determined by the Investigator Using International Workshop on Chronic Lymphocytic Leukemia National Cancer…
Major Depressive Disorder
Primary: The SERT Binding Potential (BP) --(Only the Treatment Group Was Assessed) — 0.34 a ratio of target region to background
HIV Infection
Primary: Number of Participants With Serum Creatinine Event of Grade 1 or Higher — 1 Participants
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
Smoking
Primary: Latency (Min) to Initiate Ad-lib Smoking Session — 11.304; 32.128; 27.557; 23.474 minutes
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Lupus Erythematosus, Systemic
Primary: Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 59.9; 39.2; 40.1 Percentage of participants — p=0.076
Marijuana Use
Primary: Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose. — 8.0; 25.0; 6.7; 34.0 units on a scale
Depressive Disorder, Major
Primary: Baseline Values for the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 31.4; 32.0; 32.4; 32.0 Scores on a Scale
Polycystic Ovary Syndrome
Primary: Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI) — -0.008; 0.009 units on a scale — p=0.05
Atopic Dermatitis
Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Type 2 Diabetes Mellitus
Primary: Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations — 0.10; -0.12; -0.05; -0.83 percent HbA1c — p=0.0475